Since Arbutus Biopharma Corporation (NASDAQ:ABUS) and PDL BioPharma Inc. (NASDAQ:PDLI) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership of both companies.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma Corporation	5.95M	34.93	67.15M	-1.81	0.00
PDL BioPharma Inc.	110.52M	5.01	68.86M	-0.42	0.00

Table 1 demonstrates Arbutus Biopharma Corporation and PDL BioPharma Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Arbutus Biopharma Corporation and PDL BioPharma Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma Corporation	-1,128.57%	-72.9%	-32.3%
PDL BioPharma Inc.	-62.31%	-8%	-5.9%

Risk & Volatility

A beta of 1.81 shows that Arbutus Biopharma Corporation is 81.00% more volatile than Standard and Poor’s 500. Competitively, PDL BioPharma Inc.’s beta is 0.65 which is 35.00% less volatile than Standard and Poor’s 500.

Liquidity

11.4 and 11.4 are the respective Current Ratio and a Quick Ratio of Arbutus Biopharma Corporation. Its rival PDL BioPharma Inc.’s Current and Quick Ratios are 10.9 and 10.6 respectively. Arbutus Biopharma Corporation has a better chance of clearing its pay short and long-term debts than PDL BioPharma Inc.

Institutional and Insider Ownership

Arbutus Biopharma Corporation and PDL BioPharma Inc. has shares owned by institutional investors as follows: 43.8% and 83.6%. Arbutus Biopharma Corporation’s share owned by insiders are 3.1%. Insiders Competitively, owned 0.8% of PDL BioPharma Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Arbutus Biopharma Corporation	10.17%	20.33%	-4.1%	-50.11%	-17.01%	15.93%
PDL BioPharma Inc.	2.44%	18.87%	22.33%	60.85%	55.56%	30.34%

For the past year Arbutus Biopharma Corporation was less bullish than PDL BioPharma Inc.

Summary

PDL BioPharma Inc. beats Arbutus Biopharma Corporation on 7 of the 10 factors.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates through two segments, Income Generating Assets and Product Sales. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies. The Product Sales segment, through its equity and loan investments, manufactures, markets, and sells prescription pharmaceutical products under the Tekturna and Tekturna HCT names in the United States; and Rasilez and Rasilez HCT names internationally for the treatment of hypertension. This segment sells its products primarily to wholesalers. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.